# Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA

Source: https://onco.cc/trials/nct05334277/  
OnCo record `nct05334277` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of furmonertinib, pemetrexed, carboplatin and bevacizumab in lung cancer, run by Sun Yat-sen University, now recruiting.

## Summary

Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA is a phase 2, randomised interventional study registered as NCT05334277 by Sun Yat-sen University, with a registry enrolment figure of 280 participants, started 2022-05-06 and due to reach its primary completion in 2025-02-28. Interventions recorded: Furmonertinib; Furmonertinib; Furmonertinib/Pemetrexed/Carboplatin; Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab. Conditions listed: Non-small Cell Lung Cancer. Primary outcome: Progression-free survival (PFS). Lung eligibility wording from the registry: "Pathologically confirmed non-squamous Non-Small Cell Lung Cancer (NSCLC);". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: FOCUS-C
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT05334277
- Phase: 2
- Setting: FurmOnertinib Mesylate With or Without Chemotherapy +/- bevacizUmab as firSt Line Treatment in Advanced Non-small Cell Lung Cancer Patients With Uncleared Epidermal Growth Factor Receptor (EGFR) Mutation Positive Circulating Tumor Cell DNA
- Sponsor: Sun Yat-sen University
- Enrolled: 280

## Sources

- ClinicalTrials.gov NCT05334277: https://clinicaltrials.gov/study/NCT05334277

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/), [Platinum agents](https://onco.cc/technologies/platinum/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Furmonertinib](https://onco.cc/drugs/furmonertinib/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- companies: [Shanghai Allist Pharmaceuticals](https://onco.cc/companies/allist/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05334277.json